News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
AlphaStreet Market update
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Lantern Pharma reported a wider-than-expected Q2 2026 net loss of $0.57 per share, primarily due to $3.6 million in non-cash warrant expenses, despite a 25% reduction in operating expenses and significant advancements in its clinical programs. The company also announced the establishment of Open-Medicine …
This article reports on the filing of a Form 8K by Lantern Pharma Inc. on August 14th. It is a brief announcement indicating a regulatory filing, without providing further details about the content of the 8K. The article is from Investing.com and is dated …
Lantern Pharma Inc. reported a consolidated net loss of $(7.07M) and an EPS of $(0.57) for Q2 2026, marking a significant increase in losses compared to the previous year, with no revenue reported. Despite the financial losses, the company continued to advance its clinical …
Lantern Pharma Inc. (NASDAQ: LTRN) announced it will host a webcast on August 14, 2026, at 9:00 a.m. ET, to discuss its second quarter 2026 operating and financial results. President and CEO Panna Sharma, along with other management team members, will also provide updates …
This article provides an in-depth price history for Lantern Pharma Inc. (LTRN) stock, offering various data points including daily prices, corporate actions, and historical performance relative to its 52-week highs and lows. It highlights how users can access and download extensive historical market data …
Lantern Pharma Inc is projected to report a loss of 38 cents per share, according to an earnings preview. This information is sourced from Refinitiv. The article provides an overview of the upcoming earnings report for the company.
Empery Asset Management LP and Ryan M. Lane have disclosed a 9.99% beneficial ownership stake in Lantern Pharma Inc. (LTRN) through a Schedule 13G filing. This stake includes 1,322,551 shares of common stock, with 479,882 shares issuable upon the exercise of warrants, all subject …
Lantern Pharma Inc. (NASDAQ:LTRN) announced the creation of Open-Medicine AI, a new entity to house its multi-agentic AI platform previously known as withZeta.ai. This spin-out involves commercial licensing agreements between the two companies and aims to allow Open-Medicine AI to pursue dedicated funding and …
Lantern Pharma (LTRN) has established Open-Medicine AI (OMAI) as a separate company to commercialize and expand its multi-agent AI co-scientist platform, initially proven in oncology, into broader disease areas. This strategic move, supported by licensing agreements, aims to capitalize on the rapidly growing AI …
This article from TradingView provides a financial data point for Lantern Pharma Inc. (NASDAQ: LTRN), specifically focusing on its enterprise value to revenue forward metric. The content indicates that while the market for LTRN was closed with no trades, this particular financial ratio is …
Lantern Pharma (Nasdaq: LTRN) has officially launched Open-Medicine AI (OMAI) as a separate company, signing commercial licensing agreements for Lantern's AI models, data, and algorithms. OMAI will commercialize and expand the multi-agent AI co-scientist platform, previously known as withZeta.ai, beyond oncology into other disease …
The article focuses on the "Price to earnings forward" metric for Lantern Pharma Inc. (NASDAQ: LTRN), indicating that the specific financial data for this metric was not available or displayed at the time of publication. It lists the company and stock exchange information, emphasizing …
This article provides a technical analysis of Lantern Pharma Inc (LTRN) stock, focusing on support, resistance, various technical indicators, and moving averages. It offers insights into the stock's current performance based on MACD, RSI, KDJ, and other indicators, categorizing signals as Buy, Sell, or …
Lantern Pharma Inc. announced that the European Medicines Agency (EMA) has approved an investigator-initiated Phase 1b/2 clinical trial for its drug LP-184 in advanced bladder cancer. This trial will be conducted in Copenhagen, Denmark, focusing on patients with advanced or metastatic urothelial carcinoma who …
Lantern Pharma's LP-184 bladder cancer trial, cleared by the EMA, will use a dual-biomarker strategy to select patients. The trial aims to address the unmet need in advanced urothelial carcinoma by targeting PTGR1 overexpression and DNA-damage-repair deficiency. This precision oncology approach, guided by Lantern's …
This article provides a detailed explanation of TradingKey's stock score methodology for Lantern Pharma Inc (LTRN), outlining the six key dimensions used for assessment: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment. It clarifies how each score is generated …
This article provides an overview of Lantern Pharma Inc's (LTRN) dividend and stock split history. It notes that the company has distributed $0.00 USD in dividends over the past five years. The page includes stock performance data and links to other company information such …
This article presents the detailed cash flow statement for Lantern Pharma Inc (LTRN), providing quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics such as net income, capital expenditures, and free cash flow, along with year-over-year percentage changes. …
The article provides a detailed breakdown of Lantern Pharma Inc's (LTRN) shareholder structure, listing major shareholders and their respective proportions, along with a classification of shareholder types. It also includes institutional shareholding data over several quarters and recent shareholder activity with changes in holdings …
This article provides a market overview for Lantern Pharma Inc. (LTRN) on the Nasdaq Stock Market, focusing on its financials within the health technology and pharmaceuticals sector. It highlights various market data and resources available through TradingView, including financial statements, statistics, and earnings, without …
Lantern Pharma (NASDAQ: LTRN) has received a Notice of Allowance from the USPTO for a patent covering biomarker-guided treatment with LP-184 (Zirdafulven) in various solid tumor cancers. The patent focuses on using a three-gene expression signature (PTGR1, PTPN14, and ASPH) to identify suitable patients. …
Lantern Pharma (NASDAQ: LTRN) has received a Notice of Allowance from the USPTO for a patent application related to its drug candidate, LP-184 (zirdafulven). The patent covers biomarker-guided methods for treating solid tumors, specifically focusing on patients with elevated expression of PTGR1, PTPN14, and …
Thomas A. Satterfield, Jr. has disclosed a 7.6% ownership stake in Lantern Pharma (LTRN), amounting to 975,000 shares of common stock. This beneficial ownership includes both sole and shared voting and dispositive power, with 95,000 shares under his sole control and 880,000 shares held …
Lantern Pharma announced that the USPTO has issued a Notice of Allowance for a patent covering biomarker-guided treatment for solid tumor cancers using their drug LP-184 (Zirdafulven). The patent focuses on identifying patients with elevated expression of three specific genes (PTGR1, PTPN14, and ASPH) …
Search by ticker symbol or company name and select a result to open its chart.